World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · cited 2×
“Furthermore, different substances have a great impact on the individual ’ s somatic health which is of particular importance as the main contributors to excess mortality in schizophrenia are somatic disorders (De Hert et al. 2011).”
BackgroundSelf-citationLefaucheur, J.-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., et al. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2014.05.021 · Cited by 2,119
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 1×
“…to prevent a suicide attempt, showed that the treatment with clozapine as compared to olanzapine was associated with a reduced risk of attempt suicide, a reduced need for hospitalization and for rescue interventions to prevent suicide compared to treatment with olanzapine (Meltzer et al. 2003).”
ResultLacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 1×
“…non-complicance, elevated rates of motor side-effects in general and during antipsychotic treatment, unemployment, homelessness, violence, incarceration, suicide and HIV infection (Mueser et al. 1990; Soyka et al. 1993; Drake et al. 2001; Hunt et al. 2002; Lacro et al. 2002; Wobrock et al. 2008).”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121 · cited 2×
“Clozapine has been approved by the FDA for the indication to reduce the risk of committing suicide in schizophrenia patients at high risk for suicide (Melt- from 15 to 65% depending on the substance type (Kovasznay et al. 1997; Buckley et al. 2009).”
BackgroundThe Lifetime Risk of Suicide in Schizophrenia: A Reexamination
Palmer, B. A., Pankratz, V. S., & Bostwick, J. M. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.3.247 · Cited by 1,026
Excess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869
Cited by
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Treatment engagement of individuals experiencing mental illness: review and update
Dixon, L. B., Holoshitz, Y., & Nossel, I. (2016) · World Psychiatry · doi:10.1002/wps.20306 · Cited by 550
Cannabis use and psychosis: a review of reviews
Hasan, A., von Keller, R., Friemel, C. M., Hall, W., Schneider, M., Koethe, D., Leweke, F. M., Strube, W., & Hoch, E. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01068-z · Cited by 257
“From a clinical perspective our results show that individuals seeking help with psychotic symptoms or diagnosed psychosis should be encouraged to stop using cannabis as recommended in various national and international schizophrenia guidelines [55–58].”
Self-citationAnxiety in Patients with Schizophrenia: Epidemiology and Management
Temmingh, H., & Stein, D. J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0282-7 · Cited by 173
Psychosocial interventions for people with both severe mental illness and substance misuse
Hunt, G. E., Siegfried, N., Morley, K., Brooke-Sumner, C., & Cleary, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001088.pub4 · Cited by 105
Metadata
- Authors
- Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthøj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2015-03-30
- Volume
- 16
- Issue
- 3
- Pages
- 142-170
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2120208819
- Cited by
- 145
- References
- 23
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. https://app.cochat.ai/papers/10.3109/15622975.2015.1009163
- The paper
- Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthøj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia. (2015). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622975.2015.1009163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.